Given that Alzheimer's disease is the most common cause of dementia (
+14), efforts to develop cognitive screening tests have focused on this patient population. Investigations of the use of cognitive screens has led to important contributions in the early detection of Alzheimer's disease, tracking of dementia progression, and assessment of the efficacy of potential drug therapies (
+14). In particular, the sensitivity of the clock-drawing test (CDT) among patients with Alzheimer's disease supports the wide use of the test as an index of the cognitive decline associated with dementia (
+15). However, the CDT is also sensitive to a variety of other psychiatric and neurologic impairments (
+15,
+16,
+17,
+18). In terms of Alzheimer's-related impairment, research using the CDT has shown that patients with Alzheimer's disease demonstrate deficiencies in their attempts to draw a clock face compared with other patients with dementia. Wolf-Klein and colleagues (
+15), for example, found that 94 percent of patients with probable Alzheimer's disease were impaired in global performance (a score of less than 6 on a scale of 1 to 10, with lower scores indicating more severe impairment), compared with only 75 percent of patients with dementia of nonspecific origin.
An analysis of patients' errors on the CDT provides an additional means of comparison. Whereas a majority of errors made by patients with Alzheimer's disease involve conceptual deficits—difficulty in the production of a clock face—patients with various subcortical dementias, vascular dementias, or Huntington's disease make relatively more spatial or planning deficits, such as leaving large gaps between some numbers on the clock face while crowding other numbers together, or other types of disorganization during reproduction of the clock face (
+18).
These planning problems are not weighted heavily in the global performance measure and likely account for the lower proportion of impairment seen in the non-Alzheimer's groups. Furthermore, the conceptual errors demonstrated by patients with Alzheimer's disease occur early in the course of their illness and appear to increase over time, resulting in a steady decline in global performance measures on the CDT (
+15,
+17). Overall, the CDT provides useful information in discriminating between functional psychoses and dementia and in differentiating between a broad range of the dementing illnesses.